Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

December 15, 2014

View Archives Issues

  • Treating Diabetes May Impact Thyroid Status

    In a longitudinal population-based study, metformin use was associated with an increased incidence of low thyroid-stimulating hormone (TSH) levels in patients with treated hypothyroidism.
  • Colchicine for Recurrent Pericarditis

    Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences.

  • Angiotensin Receptor Blockers for Hypertension

    Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects.

  • Dulaglutide Injection (Trulicity™)

    The FDA has approved a third long-acting, once-weekly, glucagon-like peptide (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus, joining exenetide ER and albiglutide. Dulaglutide is made up of two identical human-based GLP-1 analogs linked to a modified human IgG4 Fc fragment. This makes the molecule resistant to degradation by DPP-4, slows absorption, reduces renal clearance, and extends the elimination half-life to approximately 5 days. Dulaglutide is marketed by Eli Lilly as Trulicity.

  • Clinical Brief

    Briefs